Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 10, 2025 09:15 ET | Source: Research and Markets

China Leads Therapeutic Access with 74 Approved Immuno-Oncology Agents

Dublin, Dec. 10, 2025 (GLOBE NEWSWIRE) -- The "Strategic Intelligence: Immuno-oncology (2025)" has been added to ResearchAndMarkets.com's offering. The latest report delves into the dynamic...
December 02, 2025 04:10 ET | Source: Research and Markets

Abemaciclib Research Report 2025: Eli Lilly and Company Dominates the $1.6 Billion Market - Long-term Forecasts to 2029 and 2034

Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Abemaciclib Market Report 2025" report has been added to ResearchAndMarkets.com's offering.The abemaciclib market size has grown rapidly in recent...
November 27, 2025 08:58 ET | Source: Research and Markets

CD40 Agonists and CD40/L Antagonists Pipeline and Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of CD40 Agonists and CD40/L Antagonists" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...
November 13, 2025 08:25 ET | Source: Candel Therapeutics

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved...
September 22, 2025 04:32 ET | Source: Research and Markets

Growth Opportunities in the Immuno-oncology Therapeutics Market, 2024-2030: Advances in Next-Gen Immunotherapies, AI, and Biomarker-Driven Personalization are Driving Transformational Growth

Dublin, Sept. 22, 2025 (GLOBE NEWSWIRE) -- The "Growth Opportunities in the Immuno-oncology Therapeutics Market, 2024-2030" report has been added to ResearchAndMarkets.com's offering. The revenue...
September 08, 2025 10:39 ET | Source: Research and Markets

Trends & Strategies in the $54 Billion PD-1 & PD-L1 Inhibitors Market 2025: Industry Revenues Will More Than Double by 2030

Dublin, Sept. 08, 2025 (GLOBE NEWSWIRE) -- The "PD-1 & PD-L1 Inhibitors Market Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering. The PD-1 & PD-L1 Inhibitors...
September 02, 2025 06:06 ET | Source: Research and Markets

Immuno-oncology Clinical Trials Markets and Competition Report 2025-2030: Analysis by Therapy Type, Trial Phase, Indication, Sponsor Type, Trial Type, Patient Enrollment and Region

Dublin, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The "Immuno-oncology Clinical Trials Market by Therapy Type (Adoptive Cell Therapies, Cancer Vaccines, Checkpoint Inhibitors), Trial Phase (Phase I, Phase...
August 28, 2025 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

NEEDHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
July 30, 2025 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
July 09, 2025 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

NEEDHAM, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...